Biotech
-
Eli Lilly extends Purdue alliance; EMA investigates Valneva shot
The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics…
Read More » -
4 more biotechs cut staff amid market tumult
Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest…
Read More » -
Prasad’s FDA appointment pressures cell and gene therapy stocks
A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic…
Read More » -
Amgen’s Stelara biosimilar gets off to fast start
Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge…
Read More » -
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma
The FDA pushed back its decision date on Cytokinetics’ heart drug, while AstraZeneca got Phase 3 results that could help…
Read More » -
Novartis to acquire Regulus in deal for kidney disease drug
The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis…
Read More » -
Novavax says vaccine application still ‘approvable,’ despite FDA delay
Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product”…
Read More » -
Biohaven stock slides on withdrawal of European marketing application
The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some…
Read More » -
Bristol Myers says schizophrenia drug launch ‘off to a solid start’
Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily beating…
Read More » -
Roche, answering tariff threat, pledges $50B to US drug production
The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing…
Read More »